Mergers & Acquisitions ·
Lexeo Therapeutics agrees to acquire Mantle Therapeutics for $8.3M upfront plus up to $13M in milestones
LXEOLexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire Mantle Therapeutics Inc., a clinical-stage company focused on Friedreich ataxia therapies. The transaction involves $8.3 million in upfront consideration, comprising $5.3 million in cash and $3.0 million in Lexeo common stock, plus up to $13.0 million in contingent milestone payments over 12 years. Mantle’s portfolio includes clinical-stage LX3010 and preclinical programs LX3030, LX3050, and LX3070 targeting frataxin restoration. Concurrently, Lexeo announced three research collaborations to evaluate cerebellar-targeted sequential dosing of its gene therapy candidate LX2006 with Weill Cornell Medicine, Vivet Therapeutics, and Apertura Gene Therapy. The company confirmed enrollment in the SUNRISE-FA 2 pivotal study for LX2006, targeting cardiomyopathy treatment. Lexeo Therapeutics is a clinical-stage biopharmaceutical company developing genetic disease treatments.